Form 4: Beam Therapeutics Director Receives Stock Option Grant

Director Chirfi Guindo was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Summary

• Director Chirfi Guindo received a grant of 19,676 stock options on June 3, 2026.
• The options have an exercise price of $29.55 per share.
• The grant is scheduled to vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the board of directors.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members, particularly in high-growth gene editing companies like Beam Therapeutics.

Comparison to Industry Standards

• The grant structure follows standard industry practices for board compensation in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common governance practices to ensure board continuity.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 3, 2027, or the 2027 annual meeting of stockholders.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Options, Equity Compensation, Biotech